Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 20 Issue 7, July 2021

Volume 20 Issue 7

Navigating CAR-T cells through the solid-tumour microenvironment, inspired by the Review on p531.

Cover design: S. Harris

Comment

  • Comment |

    Misconceptions about translation — defined as the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals — hinder efforts to close gaps and address challenges related to the translational process. This article highlights some misconceptions with the aim of improving understanding and advancing solutions.

    • Christopher P. Austin

News & Analysis

Research Highlights

Reviews

  • Review Article |

    Protein arginine methyltransferases (PRMTs) regulate numerous biological processes, including transcription, splicing and the DNA damage response. In this article, Barsyte-Lovejoy and colleagues discuss the development of PRMT inhibitors, predominantly for cancer, and describe the challenges and potential new indications in which PRMT inhibition could be therapeutically relevant.

    • Qin Wu
    • Matthieu Schapira
    • Dalia Barsyte-Lovejoy
  • Review Article |

    Chimeric antigen receptors (CARs) have shown limited efficacy in the treatment of solid tumours. In this Review, Chen and colleagues discuss various engineering strategies to overcome the obstacles that the tumour microenvironment poses to CAR-T cells, to produce next-generation T cells with enhanced specificity and sustained function for the treatment of solid tumours.

    • Andrew J. Hou
    • Laurence C. Chen
    • Yvonne Y. Chen
  • Review Article |

    Twenty years have passed since the first small-molecule protein kinase inhibitor, imatinib, gained FDA approval. Here, Cohen et al. review advances in improving the potency and specificity of small-molecule protein kinase inhibitors and assess approaches to overcome the challenge of drug resistance. Applications of these compounds in cancers and other disorders, as well as future directions in the field, are discussed.

    • Philip Cohen
    • Darren Cross
    • Pasi A. Jänne

Search

Quick links